[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615385":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":24,"responsibleParty":39,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"High-risk group",null,"High-risk recurrence groups identified by the multi-omics model",{"label":13,"type":10,"description":14,"interventionNames":10},"Low-risk group","Low-risk recurrence groups identified by the multi-omics model",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Kezhong Chen","CONTACT","+86-010-88325983","mdkzchen@163.com",{"name":22,"role":18,"phone":19,"phoneExt":10,"email":23},"Yue He","hy771999@163.com",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Beijing","Beijing Municipality","100044","China",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":22,"role":18,"phone":19,"phoneExt":10,"email":23},{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chen KeZhong","Professor","100615385",false,"NCT07291921","To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Male or female, aged ≥ 18 and \\\u003C 85 years.\n3. Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.\n4. Tumor tissue and blood samples obtainable at all protocol-specified time-points.\n5. No pure ground-glass nodule on imaging.\n6. Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.\n\nExclusion Criteria:\n\n1. Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate\u002Finadequate histology.\n2. Insufficient or poor-quality blood or tissue samples.\n3. Pure ground-glass nodule on imaging.\n4. History of any malignancy within the past 5 years.\n5. Contraindication to surgery preventing radical resection.\n6. Non-radical (R2) resection.\n7. Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections.\n8. Refusal or withdrawal of informed consent.\n9. Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up).","ALL","18 Years","85 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.",[57,58,59,60],"Lung Neoplasms","Neoadjuvant Therapy","Immunotherapy","Minimal Residual Disease",[62,63,64,65,66,67,68],"NSCLC","Neoadjuvant immunotherapy","Perioperative monitoring","Liquid biopsy","MRD","Minimal residual disease","Multiple omics","2026-02-27",{"date":71,"type":72},"2026-03-03","ACTUAL",{"date":74,"type":72},"2025-05-08",{"date":76,"type":53},"2027-10-31",{"name":5,"class":6},1]